Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib with Chemo in Ovarian Cancer
NCT04590625Phase 2Unknown
- Sponsor
- Xiamen University Zhongshan Hospital
- Start
- Oct 2020
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib in epithelial ovarian cancer (EOC), sponsored by Xiamen University Zhongshan Hospital. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on NCT04590625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04590625.